Cargando…

Immune biomarker correlates from a Phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM)

Detalles Bibliográficos
Autores principales:	Lapointe, Réjean, Jamal, Rahima, van Kempen, Leon, Thebault, Pamela, Belanger, Karl, Friedmann, Jennifer, Ayoub, Jean-Pierre, Cocolakis, Eftihia, Kazemi, Shirin, Dionne, Jeanne, Lambert, Caroline, Le, Huy, Grange, Cecile, Cailhier, Jean-Francois, Spatz, Alan, Miller, Wilson
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649557/ http://dx.doi.org/10.1186/2051-1426-3-S2-P259

Ejemplares similares

Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma
por: Jamal, Rahima, et al.
Publicado: (2017)

Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)
por: Puzanov, Igor
Publicado: (2015)

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma
por: Slingluff, Craig L., et al.
Publicado: (2021)

Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience
por: Page, David B, et al.
Publicado: (2014)

Immuno-oncology safety education experience: Key lessons from ipilimumab (IPI)
por: Bartell, Heddy, et al.
Publicado: (2015)

Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma
por: Puzanov, Igor, et al.
Publicado: (2013)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Simplicity at the cost of predictive accuracy in diffuse large B‐cell lymphoma: a critical assessment of the R‐IPI, IPI, and NCCN‐IPI
por: Biccler, Jorne, et al.
Publicado: (2017)

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
por: Assouline, Sarit, et al.
Publicado: (2012)

Interim (18)F-FDG PET/CT improves the prognostic value of S-IPI, R-IPI and NCCN-IPI in patients with diffuse large B-cell lymphoma
por: Jiang, Maoqing, et al.
Publicado: (2017)

Resistance to Cancer Treatment: The Role of Somatic Genetic Events and the Challenges for Targeted Therapies
por: Batist, Gerald, et al.
Publicado: (2011)

PB2103: CAN WE ACCURATELY PREDICT SURVIVAL IN DIFFUSE LARGE B CELL LYMPHOMA IN THE RITUXIMAB ERA? RETROSPECTIVE COMPARISON OF IPI, AAIPI, R-IPI AND NCCN-IPI
por: Chorão, P., et al.
Publicado: (2022)

Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
por: Esfahani, Khashayar, et al.
Publicado: (2019)

IPI、NCCN-IPI及年龄调整的IPI评分系统在弥漫大B细胞淋巴瘤患者中的预后价值比较
Publicado: (2018)

Innate immunity activation in the early brain injury period following subarachnoid hemorrhage
por: Gris, Typhaine, et al.
Publicado: (2019)

IPyE : psicología y educación : revista del Instituto de Psicología y Educación de la Universidad Veracruzana /
Publicado: (2008)

Pre-operative immunotherapy with tumor cryoablation (cryo) plus ipilimumab (ipi) induces potentially favorable systemic and intratumoral immune effects in early stage breast cancer (ESBC) patients
por: Page, David B, et al.
Publicado: (2015)

Record linkage improves assessment of interpregnancy interval (IPI)
por: Roberts, Christine, et al.
Publicado: (2017)

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
por: Gibney, Geoffrey T., et al.
Publicado: (2019)

A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol
por: Brown, Nicholas F., et al.
Publicado: (2020)

A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
por: Brohl, Andrew S., et al.
Publicado: (2016)

Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection
por: Fujimura, Taku, et al.
Publicado: (2019)

A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma
por: Drysdale, Erik, et al.
Publicado: (2019)

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
por: Yang, Liu, et al.
Publicado: (2023)

Matched T cell repertoire analysis of peripheral blood and tumor-infiltrating lymphocytes (TILs) in early stage breast cancer (ESBC) patients (pts) treated with pre-operative cryoablation (cryo) and/or Ipilimumab (Ipi)
por: Page, David B, et al.
Publicado: (2014)

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence
por: Weber, Jeffrey, et al.
Publicado: (2015)

Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer
por: Horinouchi, Hidehito, et al.
Publicado: (2015)

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
por: Revicki, Dennis A, et al.
Publicado: (2012)

Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy‐naive advanced melanoma
por: Namikawa, Kenjiro, et al.
Publicado: (2020)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
por: Ye, Zhuo-miao, et al.
Publicado: (2022)

Experimental determination of an Ipi=2- ground state in Cu-72, Cu-74
por: Flanagan, KT, et al.
Publicado: (2010)

Molecular Determinants of Resistance Activation and Suppression by Phytophthora infestans Effector IPI-O
por: Chen, Yu, et al.
Publicado: (2012)

A Role of hIPI3 in DNA Replication Licensing in Human Cells
por: Huang, Yining, et al.
Publicado: (2016)

Perceptions of Own Illness among the Elderly as Measured by the Brief-IPQ Scale and the IPIS
por: Pawlikowska-Łagód, Katarzyna, et al.
Publicado: (2022)

CLL-IPI applied in Binet A CLL: a nationwide cohort study
por: Rotbain, Emelie C., et al.
Publicado: (2022)

Ipilimumab
Publicado: (2012)

Real‐world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance
por: Yamazaki, Naoya, et al.
Publicado: (2020)

Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma
por: Yang, Liu, et al.
Publicado: (2022)

Distinct Tryptophan Catabolism and Th17/Treg Balance in HIV Progressors and Elite Controllers
por: Jenabian, Mohammad-Ali, et al.
Publicado: (2013)

Correction: Distinct Tryptophan Catabolism and Th17/Treg Balance in HIV Progressors and Elite Controllers
por: Jenabian, Mohammad-Ali, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_nhqd9qv1n0hhjrl71toosl2caf